XSES
H02
Market cap2.33bUSD
Sep 17, Last price
13.41SGD
1D
0.45%
1Q
-16.71%
Jan 2017
47.52%
Name
Haw Par Corporation Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business activities are structured into three main segments: Healthcare, Investments, and Others. Its Healthcare segment primarily produces and distributes topical pain relief solutions, prominently featuring the Tiger Balm and Kwan Loong brands. The Investments segment focuses on acquiring publicly traded securities. Additionally, Haw Par owns and leases out a diverse portfolio of investment properties, comprising 45,324 square meters of commercial and industrial real estate across Singapore and Malaysia. The corporation also offers family and tourist-oriented leisure experiences, notably through oceanariums. Furthermore, it provides leasing services for land, buildings, and office spaces, in addition to offering management support.
Key people
Sien Hao Tarn
Group General Manager · since 2012
Say Suan Chow
Group Finance Controller · since 2019
Ah Kuan Han
Executive Non-Independent Director
President, Chief Executive Officer, Executive Director · since 2003
Director & General Manager - Manufacturing of Haw Par Healthcare Limited · since 2006
Jasmin Hong
General Manager - Marketing of Haw Par Healthcare Limited · since 2014
Chua Keeth
Deputy General Manager - Marketing of Haw Par Healthcare Limited · since 2011
Mui Lick Kow
Senior Manager - Quality & Regulatory Affairs of Healthcare
Wah Tong Ng
Deputy General Manager - Manufacturing of Healthcare · since 2013
Siew Leng Shiu
Group Internal Audit Manager · since 2014
Sung Tze Whang
General Manager - Underwater World Pattaya Ltd · since 2011
Kay Swee Lee
Legal Counsel & Company Secretary · since 2019
Choon Soo Chew
Non-Executive Independent Director · since 2019
Kia Ngee Chew
Non-Executive Independent Director · since 2011
Non-Executive Independent Director · since 2014
Non-Executive Independent Director · since 1986
Suan Yew Lee
Non-Executive Independent Director · since 1995
Non-Executive Independent Director · since 2011
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||